Today in the US, millions of individuals suffer from autoimmune diseases with Rheumatoid Arthritis and Immune Thrombocytopenia representing both large and niche markets.
Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product candidate, PRTX-100, is an immunomodulatory protein produced by bacteria that is known to modify aspects of the human immune system potentially leading to beneficial effects in autoimmune conditions. PRTX-100 has been granted Orphan Drug Designation for the treatment of ITP and its profile has been characterized in six completed and 2 ongoing clinical studies. In those trials in adult patients with active RA or ITP, PRTX-100 has been found to be generally safe and well tolerated at dose levels tested so far. Positive therapeutic effects have been seen in RA patients and ITP patients. Preclinical investigations are ongoing in other autoimmune conditions. There is potential for benefits compared to, or used in combination with, currently available treatments.